How VYNDAMAX® (tafamidis) works

In a clinical trial, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in people with ATTR-CM.

Transthyretin (TTR) is an important protein primarily produced in the liver. TTR carries thyroxine (a thyroid hormone) and retinol (vitamin A) throughout the body. TTR is mostly made in the liver but is also made in smaller amounts in the outer lining of the brain and retina.

ATTR-CM occurs when the TTR protein weakens and becomes unstable.

VYNDAMAX (tafamidis) attaching to unstable transthyretin protein icon. See Safety Info

Attach

VYNDAMAX attaches to the TTR protein.

VYNDAMAX (tafamidis) stabilizing unstable transthyretin protein icon. See Safety Info

Stabilize

VYNDAMAX stabilizes TTR, helping it stay together.

VYNDAMAX (tafamidis) outlined heart icon. See Safety Info

Maintain

By stabilizing TTR, VYNDAMAX slows the breakdown and buildup of dangerous deposits, which can help to slow the progression of ATTR-CM.




By slowing the breakdown and buildup of dangerous TTR deposits, VYNDAMAX can help slow the progression of ATTR-CM.